Pandemics past and present have been caused when pathogens – germs that cause disease – move between animals and humans, […]
Hepatitis D
Gilead Sciences is all about cancer these days, right? Well, no: The speedy authorization of remdesivir in COVID-19 saw its […]
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker […]
Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already […]
A team led by INRS Professor Patrick Labonté has identified the role of a key process in the replication cycle […]
This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C […]
Small study found more than half of patients had near undetectable viral loads by end of treatment BOSTON — Triple […]